Trial Profile
An Open-Label, Phase 1/2, Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Patients With Progressive Advanced Castration-Resistant Prostate Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 17 Nov 2023
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary)
- Indications Prostate cancer
- Focus First in man; Proof of concept; Therapeutic Use
- Sponsors Aragon Pharmaceuticals
- 08 Nov 2023 Planned End Date changed from 31 Dec 2023 to 1 Dec 2024.
- 30 Aug 2022 Planned End Date changed from 30 Jun 2022 to 31 Dec 2023.
- 12 Jan 2022 Results (n=303) assessing dermatologic adverse events frequency and time to onset and characterize clinicopathologic features in a large cohort of PCa patients treated with apalutamide and recommend management strategies based on multidisciplinary (oncologist-dermatologist) experience from 7 clinical trials (NCT03009981, NCT01171898, NCT03141671, NCT03436654, NCT02903368, NCT02772588 and NCT02106507) and off-trial, published in the Journal of Urology.